AIM Rule 26 & Adviser Name

Proteome Sciences Plc ("Proteome Sciences" or "the Company")

 

17 August 2007

 

AIM Rule 26 Compliant Website and Change of Adviser Name

 

 
Proteome Sciences plc ("Proteome Sciences") today announces that the information required by Rule 26 
of the AIM Rules for Companies (February 2007) is available within the "Rule 26" section of the 
Company's website at www.proteomics.com 

The Company today also announces that with effect from 9 August 2007, the name
of the Company's nominated adviser and broker has changed to Landsbanki
Securities (UK) Limited.

 

 

Ends

 

Notes to editors:

 

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications.  It has discovered blood biomarkers
principally for stroke, vCJD, BSE, brain damage, solid organ transplant
rejection and Alzheimer's disease. The main focus of its research currently
addresses neurological, neurodegenerative, oncology and cardiovascular
conditions.

 

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification and validation of potential biomarkers and drug targets,
including specialisation in membrane proteins and protein phosphorylation. 

 

The Company has developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer®, PST®, qPST™ and TMT®.  Proteome Sciences has patent
allowances in the major global jurisdictions for isobaric tandem mass tags (TMT
®) for the manufacture and use of any type of isobaric mass tags.

 

Commercialisation is actively pursued across the portfolio of the Company's
programmes and technologies with licensing deals signed in biomarkers for
Stroke and TSEs and for ProteoSHOP®.

 

 

 

 

                                                                     

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and Frankfurt Innovations
Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its
corporate and business development staff, and has collaborative research
agreements with leading academic institutes. The Company is listed on the
Alternative Investment Market.

 

For further information please visit www.proteomics.com.

 

 

Proteome Sciences plc

 

James Malthouse, Finance Director

Email: [e-mail]

 

Christopher Pearce, Chief Executive Officer

Email: [e-mail]

 

Tel: [phone]

 

Public Relations

 

IKON Associates                          Coast Communications

Adrian Shaw                              Matt Baldwin

Tel:    [phone]               Tel:     [phone]

Mobile: [phone]               Mobile:  [phone]

Email:  [e-mail]        Email:   [e-mail]

 

 

Nominated Adviser

Landsbanki Securities (UK) Limited

Thilo Hoffman

Tel:    [phone]